• 1. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 5. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543

Comprehensive Overview of 3-Pyrrolidinecarboxylicacid,4-propyl-,(3R,4R)-rel-(9CI) (CAS No. 261896-37-1)

3-Pyrrolidinecarboxylicacid,4-propyl-,(3R,4R)-rel-(9CI), with the CAS number 261896-37-1, is a chiral pyrrolidine derivative that has garnered significant attention in pharmaceutical and chemical research. This compound, characterized by its 4-propyl substitution and (3R,4R)-relative configuration, serves as a versatile building block in organic synthesis. Its unique structural features make it valuable for designing bioactive molecules, particularly in drug discovery and asymmetric catalysis.

The growing interest in chiral intermediates like 3-Pyrrolidinecarboxylicacid,4-propyl-,(3R,4R)-rel-(9CI) aligns with the pharmaceutical industry's focus on enantioselective synthesis. Researchers are increasingly exploring its potential in developing central nervous system (CNS) therapeutics and enzyme inhibitors. The compound's pyrrolidine core is a common motif in many FDA-approved drugs, underscoring its relevance in modern medicinal chemistry.

From a synthetic perspective, the 4-propyl side chain in CAS 261896-37-1 offers intriguing possibilities for structure-activity relationship (SAR) studies. This feature is particularly relevant to researchers investigating lipophilicity modulation in drug candidates—a hot topic in optimizing pharmacokinetic properties. Recent publications have highlighted its utility in creating conformationally constrained analogs of bioactive molecules.

The stereochemistry of (3R,4R)-rel-3-Pyrrolidinecarboxylicacid makes it particularly valuable for asymmetric synthesis applications. With the pharmaceutical industry's increasing emphasis on chiral purity and enantiomeric excess, this compound serves as an important reference standard and synthetic precursor. Its applications extend to catalysis research, where it can function as a ligand or chiral auxiliary in transition metal-catalyzed reactions.

Analytical chemists working with CAS 261896-37-1 often employ advanced techniques like chiral HPLC and X-ray crystallography to characterize its purity and configuration. These methods are crucial for quality control in pharmaceutical manufacturing, especially given current regulatory emphasis on impurity profiling and polymorph characterization—key concerns in drug development pipelines.

In the context of green chemistry initiatives, researchers are investigating sustainable synthetic routes to 3-Pyrrolidinecarboxylicacid derivatives. The compound's structural features make it amenable to biocatalytic transformations, aligning with industry trends toward environmentally friendly synthesis. This approach resonates with growing consumer and regulatory demands for sustainable pharmaceuticals.

The pyrrolidine scaffold present in 261896-37-1 demonstrates remarkable versatility in medicinal chemistry. Recent patent literature reveals its incorporation into novel compounds targeting GPCRs and ion channels—two of the most important drug target classes. This explains the sustained commercial interest in this chemical entity among pharmaceutical innovators and contract research organizations.

From a regulatory standpoint, proper handling and characterization of chiral compounds like 3-Pyrrolidinecarboxylicacid,4-propyl-,(3R,4R)-rel-(9CI) are essential for ICH compliance. The compound's well-defined stereochemistry makes it particularly useful for developing analytical reference standards, addressing one of the major challenges in chiral drug development today.

The future research directions for CAS 261896-37-1 likely include exploration of its prodrug potential and investigation of its metabolic stability—two critical parameters in modern drug design. As the pharmaceutical industry continues to prioritize translational research, such specialized building blocks will remain indispensable tools for medicinal chemists worldwide.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)